Adaptive Biotechnologies plans $8M stock sale
ADPT reported a planned sale of restricted securities under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ADPT reported a planned sale of restricted securities under Rule 144. The planned transaction covers 321,324 shares of common stock to be sold through Goldman Sachs & Co. LLC. The shares have an aggregate market value of $7,959,195.48, based on the filer’s stated valuation.
The shares relate to stock options originally acquired as compensation on February 7, 2018, with the disposition described as a compensation – cashless exercise / same-day sale. At the time of this notice, 159,595,842 shares of the issuer’s common stock were outstanding, providing context for the size of the proposed sale. The proposed sale date is August 17, 2026 on the NASD market.
Key Figures
Key Terms
Rule 144 regulatory
cashless exercise financial
same-day sale financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ADPT's Form 144 filing disclose about common stock to be sold?
AI-generated analysis. How Rhea-AI works. Not financial advice.